Renal Failure drugs – likelihood of approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Renal Failure overview

Renal failure, or kidney failure, occurs when the kidneys cannot perform essential functions, leading to the buildup of waste and fluids. It presents as acute or chronic, with distinct characteristics. Acute renal failure emerges suddenly, often from severe infections, dehydration, or abrupt blood flow loss to the kidneys. Conversely, chronic renal failure develops gradually, linked to conditions like diabetes or hypertension. Symptoms encompass reduced urine output, leg swelling, fatigue, confusion, and breathlessness. Diagnosis involves blood and urine tests, plus imaging studies. Management varies, addressing underlying issues for acute cases, and incorporating lifestyle changes, medications, or dialysis for chronic cases. Severe instances may necessitate kidney transplantation. Preventive measures involve managing health conditions, hydration, and a kidney-friendly lifestyle, emphasizing regular medical check-ups for early intervention and improved outcomes.

For a complete picture of PTSR and LoA scores for drugs in Renal Failure, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.